Diplomat Pharmacy (NYSE:DPLO) announced its earnings results on Tuesday, May 7th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.26), MarketWatch Earnings reports. The company had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.17 billion. Diplomat Pharmacy had a positive return on equity of 1.38% and a negative net margin of 5.85%. The business’s quarterly revenue was down 6.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.01) EPS. Diplomat Pharmacy updated its FY19 guidance to ($0.65-0.44) EPS and its FY 2019 guidance to $-0.65–0.44 EPS.
Shares of NYSE DPLO traded up $0.04 during trading hours on Friday, reaching $4.62. The stock had a trading volume of 742,405 shares, compared to its average volume of 1,169,505. The stock has a market cap of $342.17 million, a PE ratio of 23.10 and a beta of 0.69. The company has a quick ratio of 0.66, a current ratio of 1.00 and a debt-to-equity ratio of 1.00. Diplomat Pharmacy has a fifty-two week low of $4.39 and a fifty-two week high of $28.74.
Several brokerages recently commented on DPLO. Zacks Investment Research downgraded shares of Diplomat Pharmacy from a “hold” rating to a “strong sell” rating in a report on Friday, May 10th. ValuEngine upgraded shares of Diplomat Pharmacy from a “hold” rating to a “buy” rating in a research report on Friday, May 10th. Credit Suisse Group dropped their target price on shares of Diplomat Pharmacy from $10.00 to $8.00 and set a “neutral” rating for the company in a research report on Tuesday, April 2nd. Guggenheim assumed coverage on shares of Diplomat Pharmacy in a research report on Wednesday, April 17th. They issued a “neutral” rating and a $6.00 target price for the company. Finally, Morgan Stanley dropped their target price on shares of Diplomat Pharmacy from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Monday, March 18th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $10.25.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Recommended Story: Straddles
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.